These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 16336094)

  • 1. Molecularly targeted therapy in renal cell carcinoma.
    Rathmell WK; Wright TM; Rini BI
    Expert Rev Anticancer Ther; 2005 Dec; 5(6):1031-40. PubMed ID: 16336094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Molecular targeted therapy for renal cell carcinoma].
    Kakehi Y
    Rinsho Ketsueki; 2008 Aug; 49(8):622-5. PubMed ID: 18800611
    [No Abstract]   [Full Text] [Related]  

  • 3. VEGF-targeted therapy in metastatic renal cell carcinoma.
    Rini BI
    Oncologist; 2005 Mar; 10(3):191-7. PubMed ID: 15793222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting outcome to VEGF-targeted therapy in metastatic clear-cell renal cell carcinoma: data from recent studies.
    Golshayan AR; Brick AJ; Choueiri TK
    Future Oncol; 2008 Feb; 4(1):85-92. PubMed ID: 18241003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma.
    Cho D; Signoretti S; Dabora S; Regan M; Seeley A; Mariotti M; Youmans A; Polivy A; Mandato L; McDermott D; Stanbridge E; Atkins M
    Clin Genitourin Cancer; 2007 Sep; 5(6):379-85. PubMed ID: 17956710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic pathways involved in carcinogenesis of clear cell renal cell carcinoma: genomics towards personalized medicine.
    Audenet F; Yates DR; Cancel-Tassin G; Cussenot O; Rouprêt M
    BJU Int; 2012 Jun; 109(12):1864-70. PubMed ID: 22035299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Molecular tumor board-renal cell carcinoma].
    Grünwald V; Doehn C; Goebell PJ
    Urologe A; 2019 Jul; 58(7):768-773. PubMed ID: 31175376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of response to targeted therapy in renal cell carcinoma.
    Eisengart LJ; MacVicar GR; Yang XJ
    Arch Pathol Lab Med; 2012 May; 136(5):490-5. PubMed ID: 22229848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lord of the rings: a promising novel treatment for renal cell carcinoma?
    Johansson M
    Eur Urol; 2011 May; 59(5):745-6. PubMed ID: 21276657
    [No Abstract]   [Full Text] [Related]  

  • 10. Anti-angiogenic therapy in renal cell carcinoma.
    Sharma SG; Nanda S; Longo S
    Recent Pat Anticancer Drug Discov; 2010 Jan; 5(1):77-83. PubMed ID: 19601920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Translational research in renal cell cancer. Illustrated by the example of the vascular endothelial growth factor pathway].
    Kuefer R; Autenrieth M; Herkommer K; Blum P; Merseburger A; Hofer M; Rinnab L; Gschwend J; Ringhoffer M
    Urologe A; 2006 Mar; 45(3):328, 330-5. PubMed ID: 16465522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status.
    Rini BI; Jaeger E; Weinberg V; Sein N; Chew K; Fong K; Simko J; Small EJ; Waldman FM
    BJU Int; 2006 Oct; 98(4):756-62. PubMed ID: 16827904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal cell carcinoma.
    Rini BI; Rathmell WK; Godley P
    Curr Opin Oncol; 2008 May; 20(3):300-6. PubMed ID: 18391630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma.
    Gollob JA
    Clin Genitourin Cancer; 2005 Dec; 4(3):167-74. PubMed ID: 16425993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blockade of the vascular endothelial growth factor-receptor 2 pathway inhibits the growth of human renal cell carcinoma, RBM1-IT4, in the kidney but not in the bone of nude mice.
    Karashima T; Inoue K; Fukata S; Iiyama T; Kurabayashi A; Kawada C; Shuin T
    Int J Oncol; 2007 Apr; 30(4):937-45. PubMed ID: 17332933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the loss of the von Hippel-Lindau tumor suppressor gene in renal cell carcinoma cells.
    Sutphin PD; Chan DA; Li JM; Turcotte S; Krieg AJ; Giaccia AJ
    Cancer Res; 2007 Jun; 67(12):5896-905. PubMed ID: 17575159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Target-specific therapy requires target-specific populations in the treatment of renal cell carcinoma.
    Figlin RA; Alvin H; Meinhardt CL
    Urologe A; 2004 Sep; 43 Suppl 3():S144-5. PubMed ID: 15179554
    [No Abstract]   [Full Text] [Related]  

  • 18. Renal-cell carcinoma--molecular pathways and therapies.
    Brugarolas J
    N Engl J Med; 2007 Jan; 356(2):185-7. PubMed ID: 17215538
    [No Abstract]   [Full Text] [Related]  

  • 19. Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies.
    Costa LJ; Drabkin HA
    Oncologist; 2007 Dec; 12(12):1404-15. PubMed ID: 18165617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting growth factor and antiangiogenic pathways in clear-cell renal cell carcinoma: rationale and ongoing trials.
    Hutson TE; Sonpavde G; Galsky MD
    Clin Genitourin Cancer; 2006 Dec; 5 Suppl 1():S31-9. PubMed ID: 17239282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.